SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study

CONCLUSION: Full vaccination of COVID-19 by BBIBP-CorV in immunocompromised patients such as cancer patients is safe and effective and could induce antibody response but in lower levels compared to healthy people. Probable causes to have minor antibody response found in males, older ages, individuals with BMI ≥ 25, those without past history of COVID-19 and with hematologic cancers. No significant side effects after vaccination were seen.PMID:36743671 | PMC:PMC9893850 | DOI:10.3389/fmed.2022.1095194

Source: Cancer Control - February 6, 2023 Category: Cancer & Oncology Authors: Fahimeh Safarnezhad Tameshkel Shabnam Abedin Dargoush Bahareh Amirkalali Saeedeh Javadi Ali Ghiaseddin Yousef Alimohamadi Ali Basi Mahin Jamshidi Makiani Farhad Zamani Mohammad Hadi Karbalaie Niya Source Type: research